BioVectra Announces Acquisition of Former Sunovion (Sepracor) Facility

BioVectra Inc. - Press Release

Charlottetown, PE - June 10, 2014 - BioVectra, a specialized cGMP manufacturer and developer of pharmaceutical ingredients, has announced today that it has agreed to purchase the previous Sepracor Canada Limited facility at Windsor, Nova Scotia, for an undisclosed sum.

The 55,000 sq.ft. manufacturing facility was operated as an API manufacturing facility from 1997 to 2013, with four API's having been produced for commercial use at the site. In addition to supporting the US market, the site is registered to supply Active Pharmaceutical Ingredients (API's) to Japan. The facility includes multiple process areas, cGMP warehousing and storage space, and state of the art analytical laboratories which were used for clinical supply and process development activity, as well as production support.

BioVectra has an ongoing number of supply relationships with several pharmaceutical clients for the exclusive supply of API's, and intends to utilize existing facility infrastructure as well as evaluate plans to retrofit open process areas to serve additional volume demands for its manufacturing services. The location of the facility in close proximity to its current operation, but serviced by a transportation infrastructure and routes that are distinct from its current one, will be attractive to its client base as a potential alternative, or second manufacturing site to its Charlottetown facilities.

"We are pleased to reach agreement on this site acquisition, as it represents an opportunity for BioVectra to continue to grow with our client's requirements, and offer something unique in the dual-site supply model" stated Ron Keefe, CEO of BioVectra. "Our business has grown steadily, and we look forward to working with the people in the community of Windsor and surrounding areas to add to our capabilities for producing quality pharmaceutical products for our clients."

About BioVectra Inc.

BioVectra is a supplier to the global pharmaceutical industry, operating from three, FDA-inspected facilities in Prince Edward Island, Canada. The company is proficient in synthetic organic chemistry, natural extraction of bioactive compounds, PEGylation and conjugation chemistry, and fermentation of chemical and biologic molecules. BioVectra has submitted 10 product filings, including ANDA, DMF, VMF, and CMC section preparations for both the U.S. FDA and Health Canada. These filings have been made for both synthetic and biologic molecules, and include a human injectable API, as well as a final drug product.

For more information, please contact:

Heather Delage
Director, Sales & Marketing
hdelage@biovectra.com

T: (866) 883-2872 / (902) 566-9116

info@biovectra.com